Journal
VACCINE
Volume 27, Issue 46, Pages 6454-6459Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.06.017
Keywords
DNA vaccine; Plasmid; Antibiotic-free
Categories
Funding
- NIH [R43GM073394, R44GM072141, R43A1071660]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI071660] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM073394, R43GM080768, R44GM072141] Funding Source: NIH RePORTER
Ask authors/readers for more resources
To ensure safety, regulatory agencies recommend elimination of antibiotic resistance markers from therapeutic and vaccine plasmid DNA vectors. Here, we describe the development and application of a novel antibiotic-free selection system. Vectors incorporate and express a 150 bp RNA-OUT antisense RNA. RNA-OUT represses expression of a chromosomally integrated constitutively expressed counter-selectable marker (sacB), allowing plasmid selection on sucrose. Sucrose selectable DNA vaccine vectors combine antibiotic-free selection with highly productive fermentation manufacturing (>1 g/L plasmid DNA yields), while improving in vivo expression of encoded proteins and increasing immune responses to target antigens. These vectors are safer, more potent. alternatives for DNA therapy or vaccination. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available